Cargando…

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis

BACKGROUND: To comparatively investigate the differential effect of second-line tumour necrosis factor inhibitors (TNFis) versus other biological agents on cardiovascular disease (CVD) risk-associated biomarkers in patients with rheumatoid arthritis (RA). METHODS: We evaluated the serum levels of li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Virone, Alexandre, Bastard, Jean-Philippe, Fellahi, Soraya, Capeau, Jacqueline, Rouanet, Stéphanie, Sibilia, Jean, Ravaud, Philippe, Berenbaum, Francis, Gottenberg, Jacques-Eric, Sellam, Jérémie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667971/ https://www.ncbi.nlm.nih.gov/pubmed/31413865 http://dx.doi.org/10.1136/rmdopen-2019-000897

Ejemplares similares

Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’ – authors’ reply
por: Sellam, Jérémie, et al.
Publicado: (2014)

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Lymphoma complicating rheumatoid arthritis: results from a French case–control study
por: Kedra, Joanna, et al.
Publicado: (2021)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring
por: Smeele, Hieronymus T W, et al.
Publicado: (2022)

Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort
por: Meyer, Magali, et al.
Publicado: (2013)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
por: Saraux, Alain, et al.
Publicado: (2020)

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
por: Balanescu, Andra-Rodica, et al.
Publicado: (2022)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid Arthritis
por: Yokota, Kazuhiro, et al.
Publicado: (2021)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study
por: Flipo, René-Marc, et al.
Publicado: (2017)

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis
por: Kapoor, Sabrina R, et al.
Publicado: (2013)

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis
por: Nurmohamed, Michael, et al.
Publicado: (2015)

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
por: Choy, Ernest, et al.
Publicado: (2019)

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis
por: Sauer, Brian C., et al.
Publicado: (2017)

Attenuation of Rheumatoid Arthritis Through the Inhibition of Tumor Necrosis Factor–Induced Caspase 3/Gasdermin E–Mediated Pyroptosis
por: Zhai, Zeqing, et al.
Publicado: (2022)

Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials
por: Law-Wan, Johan, et al.
Publicado: (2021)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)

Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
por: Choy, Ernest H., et al.
Publicado: (2017)

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017)

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland
por: Finckh, A, et al.
Publicado: (2020)

Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2022)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2016)

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
por: Felten, Renaud, et al.
Publicado: (2023)

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
por: Kremer, Joel M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0vauk8u61777kg4q9132he5usd